Payment overview · 2025
General Payments
$5,199.12
213 reported records · 30 companies
Healthcare provider profile · identity verified
Paul S Han, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Pulmonary Disease · ENGLEWOOD, NJ · NPI 1174590558
Verified facts
What the public records show
CMS Open Payments records show Paul S Han, MD received $5,199.12 in general payments during 2025 across 213 reported records.
Noah Medical Corporation accounted for 17.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 41 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arikayce, Nucala, Ofev, Tezspire, Trelegy Ellipta, Xembify.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Linzess by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TEZSPIRE as an associated drug or biological on 22824 records involving 7320 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Tezspire by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Symbicort by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TEZSPIRE as an associated drug or biological on 33983 records involving 10291 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Tezspire by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OFEV as an associated drug or biological on 14236 records involving 6873 distinct recipient NPIs. Public Medicare Part D data also shows 157 claims for Ofev by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUCALA as an associated drug or biological on 100127 records involving 16970 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Nucala by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 369 claims for Trelegy Ellipta by this doctor in 2024.
Grifols USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Xembify as an associated drug or biological on 5209 records involving 2197 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Xembify by this doctor in 2024.
Insmed, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Arikayce as an associated drug or biological on 32500 records involving 8305 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Arikayce by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Noah Medical Corporation | Unresolved — no canonical attribution shown | $889.82 | 17.1% | 6 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $543.66 | 10.5% | 14 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $478.77 | 9.2% | 36 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $384.69 | 7.4% | 18 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $378.98 | 7.3% | 17 | 2025 |
| Avadel CNS Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $348.96 | 6.7% | 13 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $244.99 | 4.7% | 12 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $198.82 | 3.8% | 5 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $191.87 | 3.7% | 13 | 2025 |
| AERIN MEDICAL INC. | Unresolved — no canonical attribution shown | $177.16 | 3.4% | 2 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $172.71 | 3.3% | 18 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $152.23 | 2.9% | 9 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $149.49 | 2.9% | 3 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $136.92 | 2.6% | 8 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $101.22 | 1.9% | 3 | 2025 |
| Electromed, Inc. | Unresolved — no canonical attribution shown | $87.01 | 1.7% | 6 | 2025 |
| Vifor Pharma, Inc. | Unresolved — no canonical attribution shown | $66.68 | 1.3% | 4 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $60.38 | 1.2% | 3 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $59.80 | 1.1% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $55.19 | 1.1% | 3 | 2025 |
| United Therapeutics Corporation | Unresolved — no canonical attribution shown | $54.74 | 1.1% | 3 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $53.96 | 1.0% | 3 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $46.30 | 0.9% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $38.21 | 0.7% | 2 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $33.34 | 0.6% | 2 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $30.81 | 0.6% | 2 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $17.78 | 0.3% | 1 | 2025 |
| Optinose US, Inc. | Unresolved — no canonical attribution shown | $16.33 | 0.3% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.97 | 0.3% | 1 | 2025 |
| Itamar Medical Inc | Unresolved — no canonical attribution shown | $12.33 | 0.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $4,259.29 | 207 |
| Travel and Lodging | $828.65 | 3 |
| Education | $111.18 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| GALAXY Normalized: galaxy |
Device | Noah Medical Corporation | $889.82 | 6 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION, Regeneron Healthcare Solutions, Inc., SANOFI-AVENTIS U.S. LLC | $643.31 | 24 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | Amgen Inc., AstraZeneca Pharmaceuticals LP | $484.08 | 15 | 2025 |
Source payment records
|
|||||
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $449.76 | 8 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $389.11 | 31 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $368.70 | 3 | 2025 |
Source payment records
|
|||||
| LUMRYZ Normalized: lumryz |
Drug | Avadel CNS Pharmaceuticals, LLC | $348.96 | 13 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $273.53 | 10 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $191.87 | 13 | 2025 |
Source payment records
|
|||||
| RHINAER STYLUS Normalized: rhinaer stylus |
Device | AERIN MEDICAL INC. | $177.16 | 2 | 2025 |
Source payment records
|
|||||
| VIVAER STYLUS Normalized: vivaer stylus |
Device | AERIN MEDICAL INC. | $177.16 | 2 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $155.33 | 17 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $152.23 | 9 | 2025 |
Source payment records
|
|||||
| Vest Therapy Und Normalized: vest therapy und |
Device | Philips North America LLC | $136.92 | 8 | 2025 |
Source payment records
|
|||||
| EMBLAVEO Normalized: emblaveo |
Drug | ABBVIE INC. | $132.64 | 2 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $130.83 | 1 | 2025 |
Source payment records
|
|||||
| JASCAYD Normalized: jascayd |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $105.45 | 7 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $101.22 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $89.66 | 5 | 2025 |
Source payment records
|
|||||
| SMARTVEST Normalized: smartvest |
Device | Electromed, Inc. | $87.01 | 6 | 2025 |
Source payment records
|
|||||
| Zemaira Normalized: zemaira |
Biological | Vifor Pharma, Inc. | $66.68 | 4 | 2025 |
Source payment records
|
|||||
| GLASSIA Normalized: glassia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $55.19 | 3 | 2025 |
Source payment records
|
|||||
| Tyvaso Normalized: tyvaso |
Drug | United Therapeutics Corporation | $54.74 | 3 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $53.96 | 3 | 2025 |
Source payment records
|
|||||
| KEYTRUDA Normalized: keytruda |
Biological | Merck Sharp & Dohme LLC | $41.38 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $38.21 | 2 | 2025 |
Source payment records
|
|||||
| Brinsupri Normalized: brinsupri |
Drug | Insmed, Inc. | $35.84 | 3 | 2025 |
Source payment records
|
|||||
| Prolastin-C Liquid Normalized: prolastin c liquid |
Biological | Grifols USA, LLC | $32.15 | 2 | 2025 |
Source payment records
|
|||||
| AVYCAZ Normalized: avycaz |
Drug | ABBVIE INC. | $32.02 | 2 | 2025 |
Source payment records
|
|||||
| XYWAV Normalized: xywav |
Drug | JAZZ PHARMACEUTICALS INC. | $30.81 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $19.00 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $19.00 | 1 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $17.78 | 1 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $17.78 | 1 | 2025 |
Source payment records
|
|||||
| TEFLARO Normalized: teflaro |
Drug | ABBVIE INC. | $16.85 | 1 | 2025 |
Source payment records
|
|||||
| ALVESCO Normalized: alvesco |
Drug | Azurity Pharmaceuticals, Inc. | $16.74 | 1 | 2025 |
Source payment records
|
|||||
| HORIZANT Normalized: horizant |
Drug | Azurity Pharmaceuticals, Inc. | $16.60 | 1 | 2025 |
Source payment records
|
|||||
| Xhance Normalized: xhance |
Drug | Optinose US, Inc. | $16.33 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $15.97 | 1 | 2025 |
Source payment records
|
|||||
| Xembify Normalized: xembify |
Biological | Grifols USA, LLC | $14.15 | 1 | 2025 |
Source payment records
|
|||||
| WatchPATONE Normalized: watchpatone |
Device | Itamar Medical Inc | $12.33 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Arikayce arikayce |
2025 | Arikayce | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NUCALA nucala |
2025 | Nucala | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| OFEV ofev |
2025 | Ofev | 2024 | 157 | exact normalized | Medicare Part D |
| TEZSPIRE tezspire |
2025 | Tezspire | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 369 | exact normalized | Medicare Part D |
| Xembify xembify |
2025 | Xembify | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | TEZSPIRE open payments reported associated product |
CMS Open Payments — General Payments 22824 supporting records · 7320 recipient NPIs · example record 1226871881 |
Tezspire · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
51 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | TEZSPIRE open payments reported associated product |
CMS Open Payments — General Payments 33983 supporting records · 10291 recipient NPIs · example record 1206131392 |
Tezspire · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | OFEV open payments reported associated product |
CMS Open Payments — General Payments 14236 supporting records · 6873 recipient NPIs · example record 1221811762 |
Ofev · 2024 Exact normalized brand match · 1 Part D row |
157 | 19 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | NUCALA open payments reported associated product |
CMS Open Payments — General Payments 100127 supporting records · 16970 recipient NPIs · example record 1190332378 |
Nucala · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
369 | 68 |
| Grifols USA, LLC Exact reporting entity; no affiliate inference |
2025 | Xembify open payments reported associated product |
CMS Open Payments — General Payments 5209 supporting records · 2197 recipient NPIs · example record 1249529389 |
Xembify · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Insmed, Inc. Exact reporting entity; no affiliate inference |
2025 | Arikayce open payments reported associated product |
CMS Open Payments — General Payments 32500 supporting records · 8305 recipient NPIs · example record 1186254431 |
Arikayce · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
73 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 369 | 68 |
| Breo Ellipta | Fluticasone/Vilanterol | 274 | 48 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 268 | 71 |
| Prednisone | Prednisone | 232 | 74 |
| Montelukast Sodium | Montelukast Sodium | 209 | 45 |
| Ofev | Nintedanib Esylate | 157 | 19 |
| Azithromycin | Azithromycin | 153 | 65 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 140 | 26 |
| Pantoprazole Sodium | Pantoprazole Sodium | 132 | 32 |
| Dupixent Pen | Dupilumab | 115 | 12 |
| Pirfenidone | Pirfenidone | 115 | 17 |
| Roflumilast | Roflumilast | 97 | 19 |
| Azelastine Hcl | Azelastine Hcl | 96 | 37 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 96 | 24 |
| Gabapentin | Gabapentin | 93 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 81 | 21 |
| Levofloxacin | Levofloxacin | 79 | 50 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 76 | 17 |
| Rifampin | Rifampin | 75 | 22 |
| Eliquis | Apixaban | 73 | 15 |
| Furosemide | Furosemide | 63 | 15 |
| Isoniazid | Isoniazid | 63 | 15 |
| Atorvastatin Calcium | Atorvastatin Calcium | 57 | 16 |
| Arnuity Ellipta | Fluticasone Furoate | 55 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 51 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 50 | 19 |
| Amlodipine Besylate | Amlodipine Besylate | 49 | 13 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 46 | suppressed |
| Belsomra | Suvorexant | 44 | 13 |
| Cefdinir | Cefdinir | 44 | 32 |
| Alprazolam | Alprazolam | 43 | 16 |
| Ethambutol Hcl | Ethambutol Hcl | 40 | suppressed |
| Losartan Potassium | Losartan Potassium | 40 | 15 |
| Levothyroxine Sodium | Levothyroxine Sodium | 39 | suppressed |
| Methylprednisolone | Methylprednisolone | 38 | 26 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 37 | 13 |
| Simvastatin | Simvastatin | 37 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 35 | 32 |
| Duloxetine Hcl | Duloxetine Hcl | 34 | suppressed |
| Ozempic | Semaglutide | 34 | suppressed |
| Pregabalin | Pregabalin | 31 | suppressed |
| Omeprazole | Omeprazole | 30 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 30 | 11 |
| Spiriva Respimat | Tiotropium Bromide | 28 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 26 | suppressed |
| Xembify | Immune Globulin,gamma(Igg)klhw | 26 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 24 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 24 | suppressed |
| Lidocaine | Lidocaine | 23 | suppressed |
| Metformin Hcl | Metformin Hcl | 23 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 23 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 22 | suppressed |
| Mirtazapine | Mirtazapine | 22 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 21 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 21 | suppressed |
| Arikayce | Amikacin Liposomal/Neb.Accessr | 19 | suppressed |
| Clotrimazole | Clotrimazole | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 16 | suppressed |
| Allopurinol | Allopurinol | 15 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 15 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 15 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 14 | suppressed |
| Lorazepam | Lorazepam | 14 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 14 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 14 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 14 | suppressed |
| Tezspire | Tezepelumab-Ekko | 14 | suppressed |
| Voriconazole | Voriconazole | 14 | suppressed |
| Carvedilol | Carvedilol | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Lisinopril | Lisinopril | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Armodafinil | Armodafinil | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Dulera | Mometasone/Formoterol | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 12 | 11 |
| Linzess | Linaclotide | 12 | suppressed |
| Nucala | Mepolizumab | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Wakix | Pitolisant Hcl | 12 | suppressed |
| Acetazolamide | Acetazolamide | 11 | suppressed |
| Bupropion Xl | Bupropion Hcl | 11 | suppressed |
| Cefepime Hcl | Cefepime Hcl | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Movantik | Naloxegol Oxalate | 11 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 11 | suppressed |
| Xarelto | Rivaroxaban | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $5,199.12 · 213 records | Noah Medical Corporation | AIRSUPRA, ALVESCO, AVYCAZ, Arikayce, Brinsupri, CAPVAXIVE, DUPIXENT, EMBLAVEO, FASENRA, Flexitouch Plus, GALAXY, GARDASIL 9, GLASSIA, HORIZANT, INSPIRE, JASCAYD, KEYTRUDA, KRYSTEXXA, LUMRYZ, NUCALA, Nimbl, OFEV, Ohtuvayre, PAXLOVID, Prolastin-C Liquid, RHINAER STYLUS, SMARTVEST, Sunosi, TEFLARO, TEZSPIRE, TRELEGY ELLIPTA, Tyvaso, VIVAER STYLUS, Vest Therapy Und, WatchPATONE, XYWAV, Xembify, Xhance, YUPELRI, ZEPBOUND, Zemaira | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arikayce play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error